Regulatory effect of polygonatum odoratum extract on inflammatory factor tumor necrosis factor-α in Alzheimer’s disease cells

SHEN Ping LIU Hang ZENG Zhao-ming XIAO Yu-bo DENG Ling-yan LI Lan-yu MO Zhong-cheng

Acta Anatomica Sinica ›› 2025, Vol. 56 ›› Issue (5) : 548-556.

PDF(5190 KB)
Welcome to visit Acta Anatomica Sinica! Today is Chinese
PDF(5190 KB)
Acta Anatomica Sinica ›› 2025, Vol. 56 ›› Issue (5) : 548-556. DOI: 10.16098/j.issn.0529-1356.2025.05.006
Neurbiology

Regulatory effect of polygonatum odoratum extract on inflammatory factor tumor necrosis factor-α in Alzheimer’s disease cells

  • SHEN  Ping1  LIU  Hang1,2 ZENG  Zhao-ming1  XIAO  Yu-bo1,3  DENG  Ling-yan LI  Lan-yu2*  MO Zhong-cheng1,2*#br#
    #br#
Author information +
History +

Abstract

Objective To investigate the potential mechanism of action of polygonatum odoratum in treating Alzheimer’s disease through the utilization of network pharmacology and molecular docking techniques.    Methods The methods employed include target screening, Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, and molecular docking simulations to assess the binding interactions between the active compounds in polygonatum odoratum (POD) and the key target proteins associated with Alzheimer’s disease. Subsequently, lipopolysaccharide(LPS)was used to induce an inflammatory cell model in BV2 microglial cells. After treating the cell model with POD extract for 24 hours, the cells were collected, and the expression of the target genes were detected by Real-time PCR.    Results Eight active ingredients and 172 targets of POD were screened. The biological processes such as protein phosphorylation and signal transduction, protein binding and ATP binding were obtained by GO functional analysis. KEGG enrichment yielded PI3K/Akt, cAMP and other signaling pathways. The molecular docking result  showed that the active ingredient of POD had well binding activity with epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein kinase Src (SRC), tumor necrosis factor (TNF), STAT3. Through Real-time PCR experiments, the gene expressions of inducible nitric oxide synthase (iNOS), prostaglandin G/H synthase 2(PTGS2), interleukin (IL) -6, and IL-1β in the LPS-induced inflammatory cell model were significantly upregulated. After treating the inflammatory model with POD extract for 24 hours, the expression of TNF-α was significantly reduced, the expression of STAT3 was upregulated, there were no significant changes in the expressions of SRC and EGFR.    Conclusion Network pharmacology suggests polygonatum odoratum’s potential anti-Alzheimer’s effects may be mediated through its interaction with targets such as EGFR, TNF, SRC, and STAT3. The experimental results  suggest that polygonatum odoratum exerts an anti-inflammatory effect by acting on TNF-α, which may further alleviate the symptoms of Alzheimer’s disease. 

Key words

Polygonatum odoratum / Alzheimer’s disease / Network Pharmacology / BV2 cell / Real-time PCR

Cite this article

Download Citations
SHEN Ping LIU Hang ZENG Zhao-ming XIAO Yu-bo DENG Ling-yan LI Lan-yu MO Zhong-cheng. Regulatory effect of polygonatum odoratum extract on inflammatory factor tumor necrosis factor-α in Alzheimer’s disease cells[J]. Acta Anatomica Sinica. 2025, 56(5): 548-556 https://doi.org/10.16098/j.issn.0529-1356.2025.05.006

References

 [1] Shi J, Touchon J, Middleton LT, et al. Now and future: strategies for diagnosis, prevention and therapies for Alzheimer’s disease[J]. Sci Bull, 2024, 69(23): 3777-3784.
 [2] Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study[J]. Lancet Public Health, 2020, 5(12): e661-e671.
 [3] Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics[J]. Nat Rev Drug Discov, 2022, 21(4): 306-318.
 [4] Wang W, Diwu YCh, Wang DK, et al. Effectiveness and safety of Chinese herbal medicine in the treatment of mild to moderate Alzheimer’s disease patients: a systematic review of high-quality studies[J]. World Chinese Medicine, 2023, 18(1): 93-98,103. (in Chinese) 
王威, 第五永长, 王登坤, 等. 基于高质量研究系统评价中草药治疗轻度中度阿尔茨海默病患者的有效性与安全性[J] 世界中医药, 2023,18(1) 93-98,103.
 [5] Liu XM, Wang SY, Huang JW, et al. Chemical constituents, pharmacological effects, and research progress on the food development of Yuzhu[J]. Food and Drug, 2024, 26(2): 203-212. (in Chinese) 
刘学铭, 王思远, 黄建伟, 等.玉竹的化学成分、药理作用及其食品开发研究进展[J] 食品与药品, 2024, 26(2): 203-212.
 [6] Meng QL, Cui WY, Liu YJ, et al. Chemical constituents and pharmacological effects of Yuzhu: Research progress[J]. Shanghai Shanghai Journal of Traditional Chinese Medicine, 2020, 54(9): 93-98. (in Chinese) 
孟庆龙, 崔文玉, 刘雅婧, 等. 玉竹的化学成分及药理作用研究进展[J] 上海中医药杂志, 2020, 54(9): 93-98.
 [7] Luo C, Liu YJ, Chen ShSh, et al. Process optimization and antioxidant activity of water-soluble polysaccharides produced from Yuzhu by liquid fermentation with Ganoderma lucidum[J]. China Brewing, 2022, 41(11): 180-186. (in Chinese) 
罗灿, 刘玉洁, 陈劭舒, 等. 灵芝菌液体发酵玉竹产水溶性多糖的工艺优化和抗氧化性研究[J] 中国酿造, 2022, 41(11): 180-186.
 [8] Xiong J, Kang SS, Wang Z, et al. FSH blockade improves cognition in mice with Alzheimer’s disease[J]. Nature, 2022, 603(7901): 470-476.
 [9] Che X, Zheng B, Cheng D, et al. Efficacy of Yuzhu extract in rats with polycystic ovary syndrome[J]. Progress in Biochemistry and Biophysics, 2023, 50(7): 1690-1700. (in Chinese) 
车玄, 郑标, 成迪, 等. 玉竹提取物对大鼠多囊卵巢综合症的疗效研究[J] 生物化学与生物物理进展, 2023, 50(7): 1690-1700.
 [10] Huang W, Sherman BT, Lempicki RA, et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J]. Nature Protoc, 2009, 4(1): 44-57.
 [11] Ogata H, Goto S, Sato K, et al. KEGG: Kyoto Encyclopedia of Genes and Genomes[J]. Nucleic Acids Res, 1999, 27(1): 29-34. 
 [12] Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res, 2019, 47(D1): D607-D613.
 [13] Jiang J, Liu H, Zeng ZhM, et al. Network pharmacology-based investigation of the action targets and mechanisms of Chuanlianzi in the treatment of acute myeloid leukemia[J]. Journal of Xiangnan University (Medical Sciences), 2024, 26(3): 7-12, 20. (in Chinese) 
姜津, 刘航, 曾昭明, 等. 基于网络药理学探讨川楝子治疗急性髓细胞性白血病的作用靶点与机制[J]. 湘南学院学报(医学版), 2024, 26(3): 7-12, 20.
 [14] Zhou M, Xu R, Kaelber DC, et al. Tumor necrosis factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis[J]. PLoS One, 2020, 15(3): e0229819.
 [15] Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease[J]. Neurology, 2009, 73(10): 768-774.
 [16] Versele R, Sevin E, Gosselet F, et al. TNF-α and IL-1β modulate blood-brain barrier permeability and decrease amyloid-β peptide efflux in a human blood-brain barrier model[J]. Int J Mol Sci, 2022, 23(18): 10235.
 [17] Chang R, Knox J, Chang J, et al. Blood-brain barrier penetrating biologic TNFα inhibitor for Alzheimer’s disease[J]. Mol Pharm, 2017, 14(7): 2340-2349.
 [18] Zhang B, Wan H, Maierwufu M, et al. STAT3 ameliorates truncated tau-induced cognitive deficits[J]. Neural Regen Res, 2024, 19(4): 915-922.
 [19] Wang L, Chiang HC, Wu W, et al. Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss[J]. Proc Natl Acad Sci USA, 2012, 109(41): 16743-16748.
 [20] Scanlon DP, Bah A, Krzeminski M, et al. An evolutionary switch in ND2 enables Src kinase regulation of NMDA receptors[J]. Nat Commun, 2017, 8: 15220.
 [21] Vissel B, Krupp JJ, Heinemann SF, et al. A use-dependent tyrosine dephosphorylation of NMDA receptors is independent of ion flux[J]. Nat Neurosci, 2001, 4(6): 587-596.
PDF(5190 KB)

Accesses

Citation

Detail

Sections
Recommended

/